Viracta Therapeutics, Inc. (VIRX)

USD 0.02

(14.44%)

Long Term Debt Summary of Viracta Therapeutics, Inc.

  • Viracta Therapeutics, Inc.'s latest annual long term debt in 2023 was - USD , down -100.0% from previous year.
  • Viracta Therapeutics, Inc.'s latest quarterly long term debt in 2024 Q1 was - USD , down 0.0% from previous quarter.
  • Viracta Therapeutics, Inc. reported annual long term debt of 24.87 Million USD in 2022, up 388.07% from previous year.
  • Viracta Therapeutics, Inc. reported annual long term debt of 5.09 Million USD in 2021, up 5.9% from previous year.
  • Viracta Therapeutics, Inc. reported quarterly long term debt of - USD for 2024 Q2, down 0.0% from previous quarter.
  • Viracta Therapeutics, Inc. reported quarterly long term debt of - USD for 2023 Q3, down -100.0% from previous quarter.

Annual Long Term Debt Chart of Viracta Therapeutics, Inc. (2023 - 2005)

Historical Annual Long Term Debt of Viracta Therapeutics, Inc. (2023 - 2005)

Year Long Term Debt Long Term Debt Growth
2023 - USD -100.0%
2022 24.87 Million USD 388.07%
2021 5.09 Million USD 5.9%
2020 4.81 Million USD 1669.49%
2019 272 Thousand USD 0.0%
2018 - USD 0.0%
2017 - USD -100.0%
2016 11.1 Million USD 0.0%
2015 - USD 0.0%
2014 - USD -100.0%
2013 9.02 Million USD -48.87%
2012 17.65 Million USD 86.72%
2011 9.45 Million USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD -100.0%
2007 1.35 Million USD 41.54%
2006 955.69 Thousand USD -26.82%
2005 1.3 Million USD 0.0%

Peer Long Term Debt Comparison of Viracta Therapeutics, Inc.

Name Long Term Debt Long Term Debt Difference
America Great Health 1.12 Million USD 100.0%
Ampio Pharmaceuticals, Inc. - USD NaN%
Aridis Pharmaceuticals, Inc. 1.29 Million USD 100.0%
Biora Therapeutics, Inc. 43.73 Million USD 100.0%
Bio-Path Holdings, Inc. 10 Thousand USD 100.0%
Better Therapeutics, Inc. 10.34 Million USD 100.0%
Calithera Biosciences, Inc. 136 Thousand USD 100.0%
Comera Life Sciences Holdings, Inc. 120.3 Thousand USD 100.0%
Gene Biotherapeutics, Inc. - USD NaN%
eFFECTOR Therapeutics, Inc. - USD NaN%
Eloxx Pharmaceuticals, Inc. 8.69 Million USD 100.0%
Evelo Biosciences, Inc. 48.87 Million USD 100.0%
Evolutionary Genomics, Inc. 3.74 Million USD 100.0%
Finch Therapeutics Group, Inc. 28.4 Million USD 100.0%
Galera Therapeutics, Inc. 151.04 Million USD 100.0%
Innovation1 Biotech Inc. 218.99 Thousand USD 100.0%
Kiromic BioPharma, Inc. 911.5 Thousand USD 100.0%
Molecular Templates, Inc. 9.74 Million USD 100.0%
Navidea Biopharmaceuticals, Inc. 1.87 Million USD 100.0%
NexImmune, Inc. - USD NaN%
Orgenesis Inc. 19.06 Million USD 100.0%
Panbela Therapeutics, Inc. 4.19 Million USD 100.0%
Point of Care Nano-Technology, Inc. - USD NaN%
PaxMedica, Inc. Common Stock - USD NaN%
Scopus BioPharma Inc. - USD NaN%
Sorrento Therapeutics, Inc. 104.33 Million USD 100.0%
Statera Biopharma, Inc. 11.43 Million USD 100.0%
TRACON Pharmaceuticals, Inc. 732 Thousand USD 100.0%
Trevena, Inc. 35.23 Million USD 100.0%
Vaxxinity, Inc. 13.26 Million USD 100.0%
Vaccinex, Inc. 26 Thousand USD 100.0%
Vicapsys Life Sciences, Inc. - USD NaN%
ZIVO Bioscience, Inc. - USD NaN%